• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

NVIDIA Makes Drug Discovery, Medical Imaging, and Genomics Easier with Cloud-Based AI

by Fred Pennic 05/03/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Harnessing the power of AI for healthcare just got simpler. NVIDIA announced the integration of NVIDIA NIM, a collection of cloud-native AI microservices, with Amazon Web Services (AWS). 

– The strategic collaboration empowers developers to leverage pre-trained AI models for drug discovery, medical imaging analysis, and genomics research – all accessible through user-friendly APIs.

Streamlined Access to Powerful AI Tools

NIM integrates seamlessly with popular AWS services like SageMaker (for machine learning model development) and ParallelCluster (for high-performance computing). Additionally, AWS HealthOmics, a specialized service for biological data analysis, can orchestrate NIM workflows. This integration simplifies the process of deploying cutting-edge AI models for healthcare and life sciences companies already using the AWS cloud infrastructure.

Benefits of NVIDIA NIM on AWS

  • Faster Development: Researchers can bypass complex model development and packaging, accelerating the deployment of generative AI solutions.
  • Multimodal Workflows: NIM facilitates the creation of workflows combining AI models from various sources, like protein sequences, medical images, and patient records.
  • Enhanced Drug Discovery: BioNeMo, a foundation for AI models in drug discovery, is included in NIM. Companies like Amgen are already utilizing BioNeMo to train protein design models.

Real-World Examples of Success

  • A-Alpha Bio: This company developing protein interaction prediction tools saw a 10x speedup by utilizing BioNeMo models optimized for NVIDIA GPUs on AWS.
  • Agilent: This life sciences leader used NVIDIA Parabricks, a genomics analysis tool within NIM, to significantly improve processing speeds for variant calling workflows.

Beyond Drug Discovery and Genomics

NIM offers more than just scientific applications. It also includes:

  • Large Language Models: These powerful language processing tools can be used to create conversational AI healthcare assistants for patient education and clinician support.
  • Visual Generative AI: This technology allows for the development of digital avatars and chatbots for a more engaging user experience.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Redesign Health Study: 71% of Health Systems Adopt an "Epic-First" AI Purchasing Strategy

Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy

iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

M&A: iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

mount-sinai-launches-epic-chart-with-art-nursing-ambient-ai

Mount Sinai Medical Center Extends Epic’s Ambient AI to Inpatient Nursing

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |